Oil & Gas



Refer to important disclosures at the end of this report

PM Modi commits to bringing gas under GST, but more clarity awaited

- Prime Minister Modi yesterday stated centre trying to eliminate the cascading effect of different taxes on gas across states to reduce cost and increase usage. He further committed to bringing natural gas under the GST regime.
- While the ruling NDA Govt including Petroleum Minister Pradhan have been vocal in supporting gas under GST, there has been significant delays in forming consensus among states in the GST Council. States like Gujarat earns Rs25bn of annual VAT from gas.
- While PM's statement adds credibility, we did not anticipate the sharp up move of gas stocks today. We note that clarity relating to GST rate, estimation of input tax credit among gas players and B2B customers and whether same will be retained or passed is lacking.
- In our coverage universe, we roughly estimate 3-9% EPS impact from potential ITC benefit. Effective taxation in gas centers like Delhi/Maharashtra/Gujarat is 14.4/27.9/29.4% for CNG and 0/13.5/6-15% for piped gas, hence the final rate would determine price action.

GST rate key to price action, Delhi with minimum effective tax to see price hikes: Currently VAT rate in major gas centers like Delhi/Maharashtra/Gujarat/UP is 0/13.5/15.0/10.0% for piped gas while for CNG union excise of 14.42% is imposed. The GST rate which fixed hence would determine the pricing action, whether hike or cut. Delhi with minimum taxation would see RSP hikes while for others 18-28% range would be neutral to positive on CNG and PNG segments respectively. Overall, due to high autofuel prices, CNG prices can easily be raised. Domestic PNG also being a sticky segment would not be affected. In case of GGL's non Morbi customers, currently FO is 16% cheaper to industrial (non MGO) PNG despite 18% GST vs 6% rebated VAT respectively. Hence, price for the B2B customers would go up, which would however be passed on to retail customers. Any change in prices incl. cuts due to GST has to be passed on as per non profiteering clause.

Our rough cut ITC benefit estimate implies 3-9% EPS impact among companies: The input tax credit (ITC) benefit is a more tangible positive as same has been a burden and with convergence of tax regimes, same can be recovered. For B2B customers, any rate hike can be recovered despite increase in final prices subject to selling product GST collection being sufficient. For industrial customers in Gujarat, hence the 6% rate currently being absorbed can be recovered. In case of gas companies, for CGD and upstream, opex involves GST payments which can be recovered from gas sales under GST regime. In case of GAIL, petchem and LPG segments where feed gas is charged VAT, would now see recovery. For GAIL, it is difficult to compute considering the interstate and point of sale treatment for different types of gas like US LNG, Qatargas LNG and APM. As per our rough cut calculations using opex and COGS for CGD-upstream and GAIL respectively, positive EPS impact from ITC 7% each on IGL/Gujarat Gas (Rs1.5/1.4bn EBITDA impact), while for ONGC/Oil India it is 3%/7% (Rs7.7/1.1bn) and GAIL 9% (Rs6.8bn), though assuming 15% VAT which is not clear as of now. As per company checks, IGL/GGL has indicated Rs1.5bn/600mn annual impact while others have not computed for the lack of clarity.

Please see our sector model portfolio (Emkay Alpha Portfolio): Oil & Gas (page 6)

Financial Snapshot (Standalone)

(Rs mn)	EPS		EV/EBI	TDA	P/E	
	FY21E	FY22E	FY21E	FY22E	FY21E	FY22E
ONGC	7.1	13.9	6.1	4.2	15.5	7.9
Oil India	4.8	10.5	10.4	7.5	25.6	11.6
GAIL	9.9	12.7	11.2	8.6	14.5	11.3
Indraprastha Gas	14.5	22.0	25.1	16.6	39.2	25.8
Gujarat Gas	17.6	22.6	16.8	13.5	27.1	21.2

Source: Company, Emkay Research

ONGC BUY CMP **Target Price** 111 130 Oil India HOLD CMP **Target Price** 122 100 BUY GAIL CMP **Target Price** 143 160 HOLD Indraprastha Gas CMP **Target Price** 568 610 Gujarat Gas BUY CMP **Target Price** 478 475

This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:

Sabri Hazarika

sabri.hazarika@emkayglobal.com +91 22 6612 1282

Tanay Gabhawala

tanay.gabhawala@emkayglobal.com +91 22 6612 1336

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Story in Charts

Exhibit 1: Natural gas taxation					
CNG Union Excise	14.42%				
VAT Rates					
Delhi	0.0%				
Maharashtra	13.5%				
Gujarat	15.0%				
Uttar Pradesh					
Andhra Pradesh	10.0% 24.5%				
Bihar	20.0%				
Dadra & NH	12.5%				
Haryana	17.5%				
Karnataka	20.0%				
Madhya Pradesh	14.0%				
Odisha	15.0%				
Punjab	3.0%				
Rajasthan	5.5%				
Tamil Nadu	5.0%				
Telengana	14.5%				
West Bengal	5.0%				

Exhibit 2: VAT Collection

Rs mn	FY19
Delhi	-
Maharashtra	5,840
Gujarat	25,720
UP	18,420
Others	12,890
Total	62,870
Source: Company, Emkay Research	

Source: Company, Emkay Research

Source: MOPNG, Emkay Research

Exhibit 3: Gujarat industrial PNG vs Fuel Oil pricing

Rs/scm	Unit	Pre Tax	Post Tax
Non MGO IPNG	Rs/scm	37.0	39.2
	Rs/cal	4.4	4.7
MGO IPNG	Rs/scm	33.3	35.3
	Rs/cal	4.0	4.2
FO	Rs/kg	35.0	41.3
	Rs/cal	3.3	3.9
FO Discount vs Non MGO			-16%
Source: Company, Emkay Research			

Exhibit 4: ITC impact due to gas under GST

Do mn	Oney	Stranded	PAT	EPS	FY22E	%		Demorko
Rs mn	Opex	ITC	Impact	Impact	EPS	70		Remarks
IGL	11,346	1,480	1,107	1.6	22.0	7%		Rs1.5bn as per Co. checks
MGL	4,591	599	448	4.5	90.4	5%		Rs0.5-1bn as per Co. checks
GGL	11,056	1,442	1,079	1.6	22.6	7%		Rs0.6bn as per Co. checks
Rs mn	Opex	Gas Opex	Stranded ITC	PAT Impact	EPS Impact	FY22E EPS	%	
ONGC	196,915	59,075	7,705	5,163	0.4	13.9	3%	
Oil India	16,579	8,290	1,081	809	0.7	10.5	7%	
Rs mn	COGS	VAT	PAT Impact	EPS Impact	FY22E EPS	%		
GAIL Petchem	42,410	5,532	4,138	0.9				
GAIL LPG	9,558	1,247	933	0.2				
GAIL Total	51,968	6,778	5,070	1.1	12.7	9%		No recent guidance, Rs3-4bn was stated 4-5years ago

Source: Company, Emkay Research

ONGC RECOMMENDATION HISTORY TABLE

Date	Closing Price	ТР	Period (months)	Rating	Analyst
15-Feb-21	98	130	12m	Buy	Sabri Hazarika
6-Jan-21	97	100	12m	Buy	Sabri Hazarika
26-Nov-20	80	100	12m	Buy	Sabri Hazarika
17-Nov-20	71	100	12m	Buy	Sabri Hazarika
27-Oct-20	67	100	12m	Buy	Sabri Hazarika
28-Sep-20	72	100	12m	Buy	Sabri Hazarika
2-Aug-20	78	100	12m	Buy	Sabri Hazarika
1-Jul-20	80	105	12m	Buy	Sabri Hazarika
6-May-20	79	100	12m	Buy	Sabri Hazarika
11-Mar-20	72	100	12m	Buy	Sabri Hazarika
16-Feb-20	103	150	12m	Buy	Sabri Hazarika
24-Jan-20	118	170	12m	Buy	Sabri Hazarika
20-Dec-19	125	170	12m	Buy	Sabri Hazarika
4-Dec-19	130	180	12m	Buy	Sabri Hazarika
16-Nov-19	136	180	12m	Buy	Sabri Hazarika
25-Oct-19	140	190	12m	Buy	Sabri Hazarika
23-Sep-19	136	190	12m	Buy	Sabri Hazarika
13-Aug-19	128	185	12m	Buy	Sabri Hazarika
10-Jun-19	165	190	12m	Buy	Sabri Hazarika
3-Jun-19	172	190	12m	Buy	Sabri Hazarika
1-Apr-18	178	185	12m	Buy	Sabri Hazarika

RECOMMENDATION HISTORY CHART



Source: Bloomberg, Company, Emkay Research

Source: Company, Emkay Research

Oil India RECOMMENDATION HISTORY TABLE

RECOMMENDATI		TABLE			
Date	Closing Price	TP	Period (months)	Rating	Analyst
12-Feb-21	116	100	12m	Hold	Sabri Hazarika
26-Nov-20	97	90	12m	Hold	Sabri Hazarika
10-Nov-20	89	90	12m	Hold	Sabri Hazarika
27-Oct-20	88	95	12m	Hold	Sabri Hazarika
28-Sep-20	89	95	12m	Hold	Sabri Hazarika
22-Aug-20	100	95	12m	Hold	Sabri Hazarika
30-Jun-20	94	95	12m	Hold	Sabri Hazarika
6-May-20	93	100	12m	Hold	Sabri Hazarika
11-Mar-20	85	100	12m	Hold	Sabri Hazarika
11-Feb-20	134	150	12m	Hold	Sabri Hazarika
24-Jan-20	142	170	12m	Hold	Sabri Hazarika
20-Dec-19	151	170	12m	Hold	Sabri Hazarika
11-Nov-19	164	205	12m	Buy	Sabri Hazarika
25-Oct-19	164	205	12m	Buy	Sabri Hazarika
23-Sep-19	152	205	12m	Buy	Sabri Hazarika
10-Aug-19	150	200	12m	Buy	Sabri Hazarika
10-Jun-19	180	220	12m	Buy	Sabri Hazarika
28-May-19	184	220	12m	Buy	Sabri Hazarika
1-Apr-19	183	220	12m	Buy	Sabri Hazarika
13-Feb-19	173	245	12m	Buy	Sabri Hazarika

RECOMMENDATION HISTORY CHART



Source: Bloomberg, Company, Emkay Research


Source: Company, Emkay Research

GAIL

RECOMMENDATION HISTORY TABLE

Date	Closing Price	TP	Period (months)	Rating	Analyst
11-Feb-21	136	160	12m	Buy	Sabri Hazarika
6-Jan-21	134	125	12m	Buy	Sabri Hazarika
27-Nov-20	103	125	12m	Buy	Sabri Hazarika
26-Nov-20	103	125	12m	Buy	Sabri Hazarika
11-Nov-20	93	125	12m	Buy	Sabri Hazarika
28-Sep-20	88	130	12m	Buy	Sabri Hazarika
18-Aug-20	97	130	12m	Buy	Sabri Hazarika
25-Jun-20	103	135	12m	Buy	Sabri Hazarika
6-May-20	95	125	12m	Buy	Sabri Hazarika
11-Mar-20	91	125	12m	Buy	Sabri Hazarika
2-Mar-20	100	160	12m	Buy	Sabri Hazarika
11-Feb-20	129	160	12m	Buy	Sabri Hazarika
24-Jan-20	130	160	12m	Buy	Sabri Hazarika
10-Dec-19	111	160	12m	Buy	Sabri Hazarika
4-Dec-19	123	160	12m	Buy	Sabri Hazarika
10-Nov-19	127	160	12m	Buy	Sabri Hazarika
25-Oct-19	123	165	12m	Buy	Sabri Hazarika
23-Sep-19	141	165	12m	Buy	Sabri Hazarika
22-Aug-19	121	150	12m	Buy	Sabri Hazarika
10-Jun-19	154	175	12m	Hold	Sabri Hazarika
6-Jun-19	158	175	12m	Hold	Sabri Hazarika
28-May-19	174	193	12m	Hold	Sabri Hazarika
1-Apr-19	177	193	12m	Hold	Sabri Hazarika

RECOMMENDATION HISTORY CHART



Source: Bloomberg, Company, Emkay Research

Source: Company, Emkay Research

Indraprastha Gas RECOMMENDATION HISTORY TABLE

Date	Closing Price	ТР	Period (months)	Rating	Analyst
11-Feb-21	569	610	12m	Hold	Sabri Hazarika
27-Nov-20	496	470	12m	Hold	Sabri Hazarika
11-Nov-20	448	470	12m	Hold	Sabri Hazarika
28-Sep-20	404	430	12m	Hold	Sabri Hazarika
27-Aug-20	407	430	12m	Hold	Sabri Hazarika
18-Jun-20	450	410	12m	Sell	Sabri Hazarika
6-May-20	468	415	12m	Sell	Sabri Hazarika
7-Feb-20	511	415	12m	Sell	Sabri Hazarika
24-Jan-20	496	380	12m	Hold	Sabri Hazarika
4-Dec-19	413	380	12m	Hold	Sabri Hazarika
8-Nov-19	418	380	12m	Hold	Sabri Hazarika
25-Oct-19	377	350	12m	Hold	Sabri Hazarika
23-Sep-19	355	350	12m	Hold	Sabri Hazarika
16-Sep-19	334	330	12m	Hold	Sabri Hazarika
1-Jul-19	305	330	12m	Hold	Sabri Hazarika
10-Jun-19	340	330	12m	Hold	Sabri Hazarika
27-May-19	330	330	12m	Hold	Sabri Hazarika
1-Apr-19	307	325	12m	Hold	Sabri Hazarika
6-Feb-19	300	325	12m	Hold	Sabri Hazarika
28-Jan-19	273	325	12m	Accumulate	Sabri Hazarika
31-Dec-18	267	325	12m	Accumulate	Sabri Hazarika
11-Dec-18	249	325	12m	Accumulate	Sabri Hazarika
6-Nov-18	273	325	12m	Accumulate	Sabri Hazarika
4-Sep-18	283	290	12m	Hold	Sabri Hazarika
11-Aug-18	300	290	12m	Hold	Sabri Hazarika
13-Jul-18	253	290	12m	Accumulate	Sabri Hazarika
8-Jun-18	279	290	12m	Accumulate	Sabri Hazarika
24-May-18	253	290	12m	Accumulate	Sabri Hazarika

RECOMMENDATION HISTORY CHART



Source: Bloomberg, Company, Emkay Research

Source: Company, Emkay Research

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Gujarat Gas RECOMMENDATION HISTORY TABLE

Date	Closing Price	ТР	Period (months)	Rating	Analyst
5-Feb-21	380	475	12m	Buy	Sabri Hazarika
27-Nov-20	349	375	12m	Buy	Sabri Hazarika
6-Nov-20	313	375	12m	Buy	Sabri Hazarika
28-Sep-20	302	365	12m	Buy	Sabri Hazarika
5-Aug-20	308	365	12m	Buy	Sabri Hazarika
6-Jun-20	286	260	12m	Hold	Sabri Hazarika
6-May-20	235	280	12m	Hold	Sabri Hazarika
6-Feb-20	302	280	12m	Hold	Sabri Hazarika
24-Jan-20	294	235	12m	Buy	Sabri Hazarika
4-Dec-19	217	235	12m	Buy	Sabri Hazarika
6-Nov-19	196	235	12m	Buy	Sabri Hazarika
25-Oct-19	178	225	12m	Buy	Sabri Hazarika
23-Sep-19	182	225	12m	Buy	Sabri Hazarika
30-Jul-19	164	200	12m	Buy	Sabri Hazarika
1-Jul-19	172	190	12m	Buy	Sabri Hazarika
10-Jun-19	186	190	12m	Buy	Sabri Hazarika
6-May-19	160	190	12m	Buy	Sabri Hazarika
1-Apr-19	145	190	12m	Buy	Sabri Hazarika
8-Mar-19	136	170	12m	Buy	Sabri Hazarika
8-Feb-19	124	170	12m	Buy	Sabri Hazarika
28-Jan-19	127	173	12m	Buy	Sabri Hazarika
31-Dec-18	134	173	12m	Buy	Sabri Hazarika
11-Dec-18	125	173	12m	Buy	Sabri Hazarika
5-Nov-18	125	173	12m	Buy	Sabri Hazarika
4-Sep-18	149	186	12m	Buy	Sabri Hazarika
13-Jul-18	152	186	12m	Buy	Sabri Hazarika
8-Jun-18	166	186	12m	Buy	Sabri Hazarika
14-May-18	177	186	12m	Buy	Sabri Hazarika

RECOMMENDATION HISTORY CHART



Source: Bloomberg, Company, Emkay Research

Source: Company, Emkay Research



Analyst: Sabri Hazarika

Contact Details

sabri.hazarika@emkayglobal.com +91 22 6612 1282

Sector

Oil & Gas

Analyst bio

Sabri Hazarika holds an MBA and comes with 11 years of research experience. His team currently covers 12 stocks in the Indian Oil & Gas space.

Emkay Alpha Portfolio – Oil & Gas

EAP sector portfolio

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight (Normalised)
Oil & Gas	10.20	10.20	0%	0	100.00
BPCL	0.39	0.43	10%	4	4.20
GAIL	0.29	0.29	1%	0	2.83
Gujarat Gas	0.09	0.08	-7%	-1	0.83
Gujarat State Petronet	0.08	0.08	1%	0	0.81
Gulf Oil Lubricants	0.00	0.05	NA	5	0.52
HPCL	0.21	0.23	10%	2	2.23
Indian Oil	0.28	0.26	-7%	-2	2.58
Indraprastha Gas	0.22	0.23	2%	0	2.24
Petronet LNG	0.21	0.21	-2%	0	2.05
Oil India	0.05	0.03	-42%	-2	0.29
ONGC	0.44	0.49	10%	5	4.76
Reliance Industries	7.94	7.82	-1%	-12	76.66
Cash	0.00	0.01	NA	0	0.02

Source: Emkay Research

* Not under coverage: Equal Weight

High Conviction/Strong Over Weight

Sector portfolio NAV

	Base					Latest
	1-Apr-19	19-Feb-20	19-Aug-20	19-Nov-20	18-Jan-21	17-Feb-21
EAP - Oil & Gas	100.0	100.0	128.2	119.9	124.5	129.8
BSE200 Neutral Weighted Portfolio (ETF)	100.0	100.7	127.4	118.9	123.7	129.0
+D (


*Performance measurement base date 1st April 2019 Source: Emkay Research

Price Performance (%)

1m	3m	6m	12m
4.3%	8.3%	1.3%	29.8%
4.3%	8.4%	1.3%	28.0%
	4.3%	4.3% 8.3%	4.3% 8.3% 1.3%

Source: Emkay Research





Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): Nifty

Please see our model portfolio (Emkay Alpha Portfolio): SMID

"Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals"

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.	
BUY	Over 15%	
HOLD	Between -5% to 15%	
SELL	Below -5%	
SELL	Below -5%	

Completed Date: 19 Feb 2021 17:07:55 (SGT) Dissemination Date: 19 Feb 2021 17:08:55 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

• This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.

• Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investors. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate¹ does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of February 18, 2021
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of February 18, 2021.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the February 18, 2021
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the February 18, 2021

	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or
General	located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating
Dubai International Financial Centre	to investments should not rely on this communication. This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 th Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

Emkay Global Financial Services Ltd. CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com